247 related articles for article (PubMed ID: 22936806)
1. Ceramide glycosylation by glucosylceramide synthase selectively maintains the properties of breast cancer stem cells.
Gupta V; Bhinge KN; Hosain SB; Xiong K; Gu X; Shi R; Ho MY; Khoo KH; Li SC; Li YT; Ambudkar SV; Jazwinski SM; Liu YY
J Biol Chem; 2012 Oct; 287(44):37195-205. PubMed ID: 22936806
[TBL] [Abstract][Full Text] [Related]
2. The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase.
Bhinge KN; Gupta V; Hosain SB; Satyanarayanajois SD; Meyer SA; Blaylock B; Zhang QJ; Liu YY
Int J Biochem Cell Biol; 2012 Nov; 44(11):1770-8. PubMed ID: 22728310
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
[TBL] [Abstract][Full Text] [Related]
4. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.
Liu YY; Gupta V; Patwardhan GA; Bhinge K; Zhao Y; Bao J; Mehendale H; Cabot MC; Li YT; Jazwinski SM
Mol Cancer; 2010 Jun; 9():145. PubMed ID: 20540746
[TBL] [Abstract][Full Text] [Related]
5. Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.
Liu YY; Hill RA; Li YT
Adv Cancer Res; 2013; 117():59-89. PubMed ID: 23290777
[TBL] [Abstract][Full Text] [Related]
6. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells.
Liu YY; Han TY; Giuliano AE; Cabot MC
J Biol Chem; 1999 Jan; 274(2):1140-6. PubMed ID: 9873062
[TBL] [Abstract][Full Text] [Related]
7. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.
Duru N; Fan M; Candas D; Menaa C; Liu HC; Nantajit D; Wen Y; Xiao K; Eldridge A; Chromy BA; Li S; Spitz DR; Lam KS; Wicha MS; Li JJ
Clin Cancer Res; 2012 Dec; 18(24):6634-47. PubMed ID: 23091114
[TBL] [Abstract][Full Text] [Related]
8. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
[TBL] [Abstract][Full Text] [Related]
9. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance.
Liu YY; Han TY; Giuliano AE; Hansen N; Cabot MC
J Biol Chem; 2000 Mar; 275(10):7138-43. PubMed ID: 10702281
[TBL] [Abstract][Full Text] [Related]
10. Ultrasound reverses chemoresistance in breast cancer stem cell like cells by altering ABCG2 expression.
Guo L; Zheng P; Fan H; Wang H; Xu W; Zhou W
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 28935760
[TBL] [Abstract][Full Text] [Related]
11. A recombinant protein TmSm(T34A) can inhibit proliferation and proapoptosis to breast cancer stem cells(BCSCs) by down-regulating the expression of Cyclin D1.
Ma X; Zhang Y; Kang Y; Li L; Zheng W
Biomed Pharmacother; 2016 Dec; 84():373-381. PubMed ID: 27668537
[TBL] [Abstract][Full Text] [Related]
12. miR-638 represses the stem cell characteristics of breast cancer cells by targeting E2F2.
Lin QY; Wang JQ; Wu LL; Zheng WE; Chen PR
Breast Cancer; 2020 Jan; 27(1):147-158. PubMed ID: 31410735
[TBL] [Abstract][Full Text] [Related]
13. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
14. Metformin mediates induction of miR-708 to inhibit self-renewal and chemoresistance of breast cancer stem cells through targeting CD47.
Tan W; Tang H; Jiang X; Ye F; Huang L; Shi D; Li L; Huang X; Li L; Xie X; Xie X
J Cell Mol Med; 2019 Sep; 23(9):5994-6004. PubMed ID: 31273952
[TBL] [Abstract][Full Text] [Related]
15. Preliminary study of the effects of β-elemene on MCF-7/ADM breast cancer stem cells.
Dong Y; Li L; Wang L; Zhou T; Liu JW; Gao YJ
Genet Mol Res; 2015 Mar; 14(1):2347-55. PubMed ID: 25867381
[TBL] [Abstract][Full Text] [Related]
16. Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Martin-Castillo B; Vellon L; Menendez JA
Cell Cycle; 2011 Nov; 10(22):3871-85. PubMed ID: 22127234
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia promotes the phenotypic change of aldehyde dehydrogenase activity of breast cancer stem cells.
Shiraishi A; Tachi K; Essid N; Tsuboi I; Nagano M; Kato T; Yamashita T; Bando H; Hara H; Ohneda O
Cancer Sci; 2017 Mar; 108(3):362-372. PubMed ID: 28012234
[TBL] [Abstract][Full Text] [Related]
18. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
[TBL] [Abstract][Full Text] [Related]
19. Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
McClements L; Yakkundi A; Papaspyropoulos A; Harrison H; Ablett MP; Jithesh PV; McKeen HD; Bennett R; Donley C; Kissenpfennig A; McIntosh S; McCarthy HO; O'Neill E; Clarke RB; Robson T
Clin Cancer Res; 2013 Jul; 19(14):3881-93. PubMed ID: 23741069
[TBL] [Abstract][Full Text] [Related]
20. A novel Lnc408 maintains breast cancer stem cell stemness by recruiting SP3 to suppress CBY1 transcription and increasing nuclear β-catenin levels.
Wen S; Qin Y; Wang R; Yang L; Zeng H; Zhu P; Li Q; Qiu Y; Chen S; Liu Y; Hou Y; Tang X; Liu M; Tu G
Cell Death Dis; 2021 May; 12(5):437. PubMed ID: 33934099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
